Thoratec Q2 Sales Up 37%; Plans To Divest ITC To Danaher Fall Through

Thoratec's second-quarter sales jumped 37% over the year-ago period, to $95.1 million, on continued adoption of the HeartMate II left ventricular assist system as both destination and bridge-to-cardiac transplant therapy, the firm reported July 29